In this study, we found that SMYD2 promotes triple-negative breast cancer development via the synergistic methylation and activation of its specific non-histone substrates, STAT3 and NF-κB, and via the methylation of histones to transcriptionally regulate the expression of gene(s) related to cancer development. The gene discussed is SMYD2; the disease is cancer.